Jump to content

Buprenorphine/naloxone: Revision history


For any version listed below, click on its date to view it. For more help, see Help:Page history and Help:Edit summary. (cur) = difference from current version, (prev) = difference from preceding version, m = minor edit, → = section edit, ← = automatic edit summary

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)

25 May 2024

17 May 2024

26 April 2024

25 April 2024

26 March 2024

21 March 2024

20 March 2024

13 February 2024

6 January 2024

20 December 2023

4 December 2023

  • curprev 20:5720:57, 4 December 2023192.251.109.39 talk 34,360 bytes −866 Mechanism clarification - Buprenorphine does not begin to act as an antagonist at higher doses, this study referenced was referring to a novel analogue of buprenorphine that has antagonistic activities. undo Tag: references removed

27 November 2023

14 November 2023

5 November 2023

3 November 2023

24 August 2023

21 August 2023

23 July 2023

10 July 2023

24 March 2023

8 February 2023

20 January 2023

6 January 2023

3 January 2023

2 January 2023

13 November 2022

6 November 2022

29 October 2022

  • curprev 04:0904:09, 29 October 2022Boghog talk contribs 32,864 bytes −337 consistent citation formatting undo
  • curprev 03:3003:30, 29 October 20222601:1c0:cc80:8d70:f121:6d8f:f4ce:de75 talk 33,201 bytes +12 →‎Adverse effects: The sentence alludes to naloxone inducing withdrawal in addicted individuals. Addiction describes behavioral risks despite knowledge of the detriments of abuse. Chemical dependence describes withdrawal symptoms upon sudden drug withdrawal. Non-addicted, non-abusing pain patients who do not exceed their prescribed doses or seek out additional opioids would still run the risk of precipitated withdrawal upon sufficient naloxone absorption from the Suboxone formulation. undo Tags: Mobile edit Mobile web edit

28 October 2022

25 October 2022

8 October 2022

6 September 2022

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)